Human Leukocyte Antigen Restricted Gamma Delta T Cell Receptors and Methods of Use Thereof
AssigneeGadeta B.V.
InventorsJürgen Herbert Ernst Kuball, Guido Joris Jan Kierkels, Zsolt Sebestyen
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods of treating a subject with cancer. The compositions and methods utilize immunoresponsive cells to effect killing of tumor cells.
Claims127
A composition comprising a polypeptide construct that selectively binds a human leukocyte antigen (HLA) molecule or portion thereof on a target cell when said HLA molecule is complexed to at least one additional HLA molecule on said target cell, wherein said polypeptide construct does not bind an uncomplexed HLA molecule, and wherein said polypeptide construct is expressed on a cell or synthesized.
A method of treating a subject in need thereof comprising administering to said subject:
- an effective amount of a pharmaceutical composition comprising a polypeptide construct that binds a human leukocyte antigen (HLA) molecule complexed to at least one additional HLA molecule, and wherein said polypeptide construct does not bind an uncomplexed HLA molecule.
A method of treating a disease comprising aberrant HLA-A*24 expression comprising administering a first therapeutic agent that binds at least a portion of a human leukocyte antigen (HLA)-A*24, and at least one of:
- subsequently re-administering said first therapeutic agent, and administering a second therapeutic agent.
An engineered cell comprising:
- a genomic alteration encoding a polypeptide construct that selectively binds a human leukocyte antigen (HLA) molecule or portion thereof on a target cell when said HLA molecule is complexed to at least one additional HLA molecule on said target cell, wherein said polypeptide construct does not bind an uncomplexed HLA molecule.
A polynucleic acid comprising a sequence that is at least 90%, 95%, 97% or 99% identical to a sequence encoding a polypeptide sequence of at least one of SEQ ID NO:
- 2, SEQ ID NO:
- 3, amino acids 19-309 of SEQ ID NO:
- 4, or amino acids 21-293 of SEQ ID NO:
- 5.
An engineered cell comprising a receptor sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to at least one of SEQ ID NO:
- 2, SEQ ID NO:
- 3, amino acids 19-309 of SEQ ID NO:
- 4, or amino acids 21-293 of SEQ ID NO:
- 5.
An engineered cell comprising at least a portion of a receptor with a sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to at least one of SEQ ID NO:
- 2, SEQ ID NO:
- 3, amino acids 19-309 of SEQ ID NO:
- 4, amino acids 21-293 of SEQ ID NO:
- 5 and SEQ ID NO:
- 6 to SEQ ID NO:
- 428.
A polypeptide that selectively binds a human leukocyte antigen (HLA) molecule or portion thereof on a target cell when said HLA molecule is complexed to at least one additional HLA molecule on said target cell, wherein said polypeptide does not bind an uncomplexed HLA molecule.
Dependencies are inferred from the claim text.